Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?
about
Ion channels and transporters in tumour cell migration and invasionAspect of thrombolytic therapy: a reviewIon transporters in brain tumorsA cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cellsGlycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer questionAttacking the supply wagons to starve cancer cells to death.Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy.The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cellsFinding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach.ENaCs and ASICs as therapeutic targets.Proton pump inhibitors for the treatment of cancer in companion animals.Molecular features of the cytotoxicity of an NHE inhibitor: Evidence of mitochondrial alterations, ROS overproduction and DNA damage.A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroCariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.Role of pHi, and proton transporters in oncogene-driven neoplastic transformation.Vascular permeability in the RG2 glioma model can be mediated by macropinocytosis and be independent of the opening of the tight junction.Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.Hydrochlorothiazide use is strongly associated with risk of lip cancer.Multiple effects of the Na(+)/H (+) antiporter inhibitor HMA on cancer cells.Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.Tumour acidosis: from the passenger to the driver's seat.Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells.Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis.
P2860
Q26849490-49AACD52-9817-4BF2-867E-05092488A064Q26999262-3E653174-E0ED-4E4C-B1B2-E0280A3CC39AQ28082580-EE9F61F5-2B7F-4EDC-9852-E7F0E0C74E49Q28487319-9B8B1734-60AA-456A-878E-0213B4591F58Q34459681-D2B91883-8B6E-4096-BA44-84AA0377243FQ34516773-FAC8A45C-304E-4517-8A19-9564566E1407Q34573748-41AFD4AF-786A-4F21-BB52-68BFC262D729Q35176066-24EDDD32-8495-4525-9787-487A8B996926Q35229098-92AE429B-DDE3-4CEB-9766-4AAB64A08B80Q35900722-CDF341C5-5B1F-417D-90B7-80E42285574FQ36027301-6B28100D-2FD7-4636-8B5D-BC91471720DAQ36183468-468E9485-EC0A-4BD0-BE8B-89BC746B508CQ36791190-DB684EF5-898D-4A91-A64A-48AAA9F4CFECQ37304956-F1B2E3BC-09B5-4C9C-AAFC-BA814EC5E617Q38184984-251AF390-2B64-43F8-A6D9-C76147280DF1Q38764263-728DB049-331D-4049-BC55-F7279DFA7A6CQ38788869-DFC3D31F-F888-42FD-B2FE-2B36161C64EFQ38798995-6E6B058E-845C-4632-B500-6D7C46C83EE2Q39101411-3F65ADE5-EACF-4822-933A-15994F6BD5BDQ46308799-D359A9E5-9398-4140-BC7C-5EF8262FB9E0Q47110708-1F0E04D7-90F1-4091-89C1-34FA5100E355Q47772621-720E9E26-765F-453B-A610-78A90CF1A8EAQ50067582-4F1042AB-F6EB-4DA4-A163-F9C58DC91675Q50137398-4AC2139D-9F99-4D7C-A65D-196F15C6A78CQ51779283-3FBA607A-42BC-45DB-8808-25D4D432F3F2Q52639519-B6DAEAB7-BD4B-4E12-99D1-5ED7E985C7BAQ53275050-928BD7A0-18C3-47B3-96CD-80A6B714C0BFQ53729565-11C2D4A0-71E1-4803-8E63-670B9B1305F0Q54478548-F16A32A0-1272-42D1-A37B-4EF4275F625A
P2860
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@ast
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@en
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@nl
type
label
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@ast
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@en
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@nl
prefLabel
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@ast
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@en
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@nl
P2860
P356
P1476
Anti-tumour/metastasis effects ...... waiting for its call-of-duty?
@en
P2093
Hayden Matthews
P2860
P304
P356
10.1002/IJC.26156
P577
2011-08-01T00:00:00Z